LUDWIG ENTERPRISES - LUDG STOCK NEWS

Ludwig Enterprises, Inc. (OTC PINK:LUDG) has entered into a partnership with Summit Bancorp to facilitate its cross-listing on the Canadian Stock Exchange (CSE). This move aims to attract a broader investor base. The company's subsidiary, Precision Genomics, is developing an mRNA Inflammatory Index (patent pending), which tracks 48 inflammation biomarkers, potentially transforming the management of chronic diseases. Ludwig's upcoming nutraceutical, NuGenea (patent pending), set for launch in Q2 2023, includes 20 ingredients intended to manage inflammation and decrease chronic disease risk. The innovations may significantly impact the healthcare sector.

Ludwig Enterprises, Inc. (OTC:LUDG) announced plans to file a Non-Offering Prospectus to facilitate its listing on the Canadian Stock Exchange in the second quarter of 2023. The company, along with its subsidiary Precision Genomics, developed a genomic mRNA microarray assay that evaluates 48 biomarkers related to chronic inflammation, with potential applications in managing various diseases, including cancer and diabetes. Ludwig's launch of the nutraceutical product NuGenea is also scheduled for the same quarter. The global mRNA therapeutics market is projected to reach $39.9 billion, highlighting significant growth opportunities for Ludwig in healthcare.

Ludwig Enterprises, Inc. is exploring growth opportunities through potential partnerships in nutraceutical products and a diabetes clinical study leveraging its proprietary mRNA Inflammatory Index. Discussions are ongoing with a foreign developer to sell their products in the U.S., aiming to capitalize on the 8.9% annual growth in the U.S. nutraceutical market. The company has collected over 1,700 samples for research on diabetes and related diseases. Ludwig's forward-looking statements emphasize the potential for increased revenue and improved health outcomes, although they acknowledge inherent risks in achieving these goals.

Ludwig Enterprises is generating significant clinical interest in its patent-pending mRNA Inflammatory Index™, which measures inflammatory biomarkers linked to chronic diseases like cancer and diabetes. The company has tested over 1,700 samples and receives over 100 new samples monthly from 28 clinics. The global mRNA therapeutics market is projected to reach $39.9 billion by 2030, driven by increasing chronic disease prevalence. Ludwig's research shows promising early results in identifying genetic differences in certain cancers. The company has IRB approval for bladder cancer studies and aims to enhance patient outcomes through its innovative genomic technology.

Ludwig Enterprises, Inc. (OTC PINK:LUDG) has announced the upcoming launch of its nutraceutical product, NuGenea, aimed at reducing chronic inflammation. Formulated with 20 carefully selected ingredients, NuGenea targets biomarkers linked to inflammation. Chief Medical Officer Dr. Marvin S. Hausman emphasized that chronic inflammation contributes to 50% of global deaths, and NuGenea could represent a significant advance in preventative health. The product is slated for sale through Amazon Prime and the company's website in Q2 2023. Ludwig Enterprises continues to innovate with its mRNA genomic technology, exploring new avenues in healthcare.

Ludwig Enterprises, Inc. (OTC PINK:LUDG) has announced a partnership with Drs. Kim Farahay and Jeff Lee to utilize the company's mRNA Inflammatory Index in enhancing Ketamine treatment for patients with Treatment Resistant Depression. The clinic, set to open in southeastern Ohio in 2023, aims to leverage this innovative program to track inflammatory markers, potentially adjusting treatment dosages based on AI analyses. With Ketamine's established efficacy for resistant depression since the early 2000s, this collaboration could represent a significant advancement in the burgeoning ketamine clinic industry.

Ludwig Enterprises has released a white paper by Dr. Marvin S. Hausman, highlighting chronic inflammation as a silent disorder impacting health. The paper cites 85 studies, focusing on 20 nutritional compounds, including NAC and CoQ10, that can reduce inflammatory cytokines. The mRNA Inflammatory Index technology, developed by Hausman, analyzes inflammation biomarkers and aims to prevent chronic diseases like diabetes and cancer. This innovative approach, combining AI and genomic tools, positions Ludwig at the forefront of personalized medicine, capable of improving patient outcomes and reducing healthcare costs significantly.

Ludwig Enterprises has announced a strategic partnership with The Fannon Group to enhance sales and marketing for its key products, including the mRNA Inflammatory Index. This patent-pending technology aims to evaluate inflammation biomarkers, potentially helping healthcare professionals in early illness detection and management. CEO Luke Fannon brings over 30 years of experience, which aims to boost the company's market presence. Ludwig's innovative approach is positioned to significantly impact the billion-dollar healthcare sector and improve patient outcomes, potentially saving costs in the industry.

Ludwig Enterprises Inc. (OTC PINK:LUDG) is advancing its application to trade on the OTCQB Market, a significant step towards future listings on the NYSE or NASDAQ. This transition is poised to enhance investor visibility and access a broader capital pool, providing crucial liquidity. The OTCQB tier requires stringent financial disclosures and maintains higher trading standards than other OTC markets. The move aims to strengthen Ludwig's potential as an investment opportunity, promoting growth and transparency for shareholders.